Abstract
Expression of the RIα subunit of cAMP-dependent protein kinase type I is enhanced in human cancer cell lines, in primary tumours, in cells after transformation and in cells upon stimulation of growth. We have investigated the effect of sequence-specific inhibition of RIα gene expression on in vivo tumour growth. We report that single injection RIα antisense treatment results in a reduction in RIα expression and inhibition of tumour growth. Tumour cells behaved like untransformed cells by making less protein kinase type I. The RIα antisense, which produces a biochemical imprint for growth control, requires infrequent dosing to halt neoplastic growth in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Krebs, E.G. Protein kinase. Curr. Topics Cell Regul. 5, 99–133 (1972).
Lohmann, S.M. & Walter, U. Regulation of the cellular and subcellular concentrations and distribution of cyclic nucleotide-dependent protein kinases. in Advances in Cyclic Nucleotide and Protein Phosphorylation Research, vol. 18, 63–117 (Raven, New York, 1984).
Cho-Chung, Y.S. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: New approaches to therapy [Perspectives in cancer research]. Cancer Res. 50, 7093–7100 (1990).
Beebe, S.J. & Corbin, J.D. Cyclic nucleotide-dependent protein kinases. in The Enzymes: Control by Phosphorylation, vol. 17, part A, 43–111 (Academic, New York, 1986).
McKnight, G.S. et al. Analysis of the cAMP-dependent protein kinase system using molecular genetic approaches. Recent Prog. Horm. Res. 44, 307–335 (1988).
Levy, F.O. et al. Molecular cloning, complementary deoxyribonucleic acid structure and predicted full-length amino acid sequence of the hormone-inducible regulatory subunit of 3′,5′-cyclic adenoslne monophosphate-dependent protein kinase from human testis. Molec. Endocrinol. 2, 1364–1373 (1988).
Uhler, M.D. et al. Isolation of cDNA clones coding for the catalytic subunit of mouse cAMP-dependent protein kinase. Proc. natn. Acad. Sci. U.S.A. 83, 1300–1304 (1986).
Uhler, M.D., Chrivia, J.C. & McKnight, G.S. Evidence for a second isoform of the catalytic subunit of cAMP-dependent protein kinase. J. biol. Chem. 261, 15360–15363 (1986).
Showers, M.O. & Maurer, R.A. A cloned bovine cDNA encodes an alternate form of the catalytic subunit of cAMP-dependent protein kinase. J. biol. Chem. 261, 16288–16291 (1986).
Beebe, S.J. et al. Molecular cloning of a unique tissue-specific protein kinase (Cγ) from human testis—representing a third isoform for the catalytic subunit of the cAMP-dependent protein kinase. Molec. Endocrinol. 4, 465–475 (1990).
Øyen, O. et al. A unique mRNA species for a regulatory subunit of cAMP-dependent protein kinase is specifically induced in haploid germ cells. FEBS Lett. 229, 391–394 (1988).
Clegg, C.H., Cadd, G.G. & McKnight, G.S. Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase. Proc. natn. Acad. Sci. U.S.A. 85, 3703–3707 (1988).
Cadd, G.G., Uhler, M.D. & McKnight, G.S. Holoenzymes of cAMP-dependent protein kinase containing the neural form of type I regulatory subunit have an increased sensitivity to cyclic nucleotides. J. biol. Chem. 265, 19502–19506 (1990).
Kapoor, C.L. & Cho-Chung, Y.S. Compartmentalization of regulatory subunits of cyclic adenosine 3′, 5′-monophosphate-dependent protein kinases in MCF-7 human breast cancer cells. Cancer Res. 43, 295–302 (1983).
Nigg, E.A., Schäfer, G., Hilz, H. & Eppenberger, H.M. Cyclic-AMP-dependent protein kinase type II is associated with the golgi complex and with centrosomes. Cell 41, 1039–1051 (1985).
Taylor, S.S. et al. cAMP-dependent protein kinase: Prototype for a family of enzymes. FASEB J. 2, 2677–2685 (1988).
Yokozaki, H. et al. An antisense oligodeoxynucleotide that depletes RIα sub-unit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. 53, 868–872 (1993).
Tortora, G., Yokozaki, H., Pepe, S., Clair, T. & Cho-Chung, Y.S. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. natn. Acad. Sci. U.S.A. 88, 2011–2015 (1991).
Sandberg, M., Tasken, K., Øyen, O., Hansson, V. & Jahnsen, T. Molecular cloning, cDNA structure and deduced amino acid sequence for A type I regulatory subunit of cAMP-dependent protein kinase from human testis. Biochem. biophys. Res. Commun. 149, 939–945 (1987).
Tortora, G., Clair, T. & Cho-Chung, Y.S. An antisense oligodeoxynucleotide targeted against the type RIIβ, regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia Cells without affecting phorbol ester effects. Proc. natn. Acad. Sci. U.S.A. 87, 705–708 (1990).
Rosen, O.M. & Erlichman, J. Reversible autophosphorylation of a cyclic 3′, 5′-AMP-dependent protein kinase from bovine cardiac muscle. J. biol. Chem. 250, 7788–7794 (1975).
Rohlff, C., Clair, T. & Cho-Chung, Y.S. 8-Cl-cAMP induces truncation and down-regulation of the RIα subunit and up-regulation of the RIIβ, subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J. biol. Chem. 268, 5774–5782 (1993).
Tagliaferri, P., Katsaros, D., Clair, T., Neckers, L., Robins, R.K. & Cho-Chung, Y.S. Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. J. biol. Chem. 263, 409–416 (1988).
Connelly, P.A., Hastings, T.G. & Reimann, E.M. Identification of a ternary complex between cAMP and a trimeric form of cAMP-dependent protein kinase. J. biol. Chem. 261, 2325–2330 (1986).
Cobb, C.E., Beth, A.H. & Corbin, J.D. Purification and characterization of an inactive form of cAMP-dependent protein kinase containing bound cAMP. J. biol. Chem. 262, 16566–16574 (1987).
Otten, A.D., Parenteau, L.A., Døskeland, S. & McKnight, G.S. Hormonal activation of gene transcription in ras-transformed NIH3T3 cells overexpressing RIIα and RIIβ subunits of the cAMP-dependent protein kinase. J. biol. Chem. 266, 23074–23082 (1991).
Nesterova, M., Budillon, A., Pepe, S., Cereseto, A. & Cho-Chung, Y.S. Introducing an autophosphorylation site mutation in the RIIβ regulatory subunit of cAMP-dependent protein kinase abolishes the RIIβ-mediated regulatory function. FASEB J. 8, A1328 (1994) (abstract).
Srivastava, A.K. & Stellwagen, R.H. Presence of the sites for interacting with cyclic AMP and with catalytic subunit on small fragments of protein kinase regulatory subunit. J. biol. Chem. 253, 1752–1755 (1978).
Wagner, R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333–335 (1994).
Iversen, P. In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetics prologue. Anti-Cancer Drug Des. 6, 531–538 (1991).
Weber, W. & Hilz, H. cAMP-dependent protein kinases I and II: Divergent turnover of subunits. Biochemistry 25, 5661–5667 (1986).
Rights and permissions
About this article
Cite this article
Nesterova, M., Cho-Chung, Y. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1, 528–533 (1995). https://doi.org/10.1038/nm0695-528
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0695-528
This article is cited by
-
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
British Journal of Cancer (2012)
-
Epidermal growth factor receptor levels are reduced in mice with targeted disruption of the protein kinase A catalytic subunit
BMC Cell Biology (2008)
-
Inherited disposition to cardiac myxoma development
Nature Reviews Cancer (2006)
-
A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers
Investigational New Drugs (2006)
-
Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion
Oncogene (2004)